Pharmacy Benefits Manager Provisions.

Added a specific definition for 'generic equivalent' that requires identical active ingredients, dosage forms, and comparable therapeutic effects, while excluding drugs with unresolved bioequivalence concerns.

Updated the definition of 'national average drug acquisition cost' to specify it must be publicly available and exclude rebates and discounts, replacing the previous reference to invoice prices.

Refined the definition of 'specialty pharmacy accreditation' to explicitly list the Utilization Review Accreditation Commission, Accreditation Commission for Health Care, and the Joint Commission as recognized bodies.

Reorganized the statute by moving pharmacy and pharmacist protections from Section 58-56A-3 to Section 58-56A-4 and updating the section number for specialty drug references from 223 to Section 223 of the Internal Revenue Code.

Added four new primary sponsors (Representatives Blackwell, Huneycutt, and Lowery) to the list of bill sponsors.

Updated the bill's internal reference number from 'DRH30073-MR-3' to 'H163-v-1' and added a specific referral date of February 24, 2025.

Removed the draft date of February 21, 2025, as it was superseded by the new official filing date.